Diagnostic Yield of Brugada Syndrome Up With Modified Leads

This article originally appeared here.
Share this content:
Diagnostic Yield of Brugada Syndrome Up With Modified Leads
Diagnostic Yield of Brugada Syndrome Up With Modified Leads

FRIDAY, April 29, 2016 (HealthDay News) -- Use of V1 and V2 leads recorded in the second and third intercostal spaces (High-ICS) increases the diagnostic yield for Brugada syndrome (BrS), according to a study published online April 21 in the Journal of Cardiovascular Electrophysiology.

Antonio Curcio, M.D., Ph.D., from the Magna Graecia University in Catanzaro, Italy, and colleagues identified 300 subjects from a Brugada syndrome registry, without a diagnostic coved ST-segment elevation in conventional V1 to V3 leads. They examined the clinical presentation and arrhythmic risk in this subgroup of patients discovered only with modified leads.

The researchers found that 21.3 percent of the patients (64 patients) were diagnosed with High-ICS. Four of the patients were diagnosed at baseline, while 60 were diagnosed after drug-challenge with sodium-channel blockers. Overall, 4.7 percent of patients with spontaneous abnormal electrocardiogram experienced cardiac events, with an annual event rate of 0.11 percent, which was similar to that of the low-risk BrS category diagnosed in standard leads.

"This study demonstrates that the use of new diagnostic criteria for BrS allows increasing the diagnostic yield by 20 percent and that the arrhythmic risk is low when BrS can be established only in High-ICS," the authors write. "We also show that the prognostic value of spontaneous electrocardiogram pattern is confirmed in this subgroup."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths